Alnylam Pharmaceuticals Inc (ALNY)vsKeros Therapeutics Inc (KROS)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
KROS
Keros Therapeutics Inc
$11.34
+3.18%
HEALTHCARE · Cap: $342.44M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 1422% more annual revenue ($3.71B vs $244.06M). KROS leads profitability with a 35.6% profit margin vs 8.5%. KROS trades at a lower P/E of 4.9x. KROS earns a higher WallStSmart Score of 53/100 (C-).
ALNY
Hold49
out of 100
Grade: D+
KROS
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Margin of Safety
-8.9%
Fair Value
$15.64
Current Price
$11.34
$4.30 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 36 of every $100 in revenue as profit
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
0.0% earnings growth
Smaller company, higher risk/reward
Revenue declined 87.3%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : KROS
The strongest argument for KROS centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 35.6% and operating margin at -75.8%.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : KROS
The primary concerns for KROS are EPS Growth, Market Cap, Revenue Growth.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while KROS is a declining play — different risk/reward profiles.
KROS carries more volatility with a beta of 0.90 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
KROS scores higher overall (53/100 vs 49/100), backed by strong 35.6% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Keros Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with a great unmet medical need. The company is headquartered in Lexington, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?